Medication info

Olmesartan Medoxomil and Rosuvastatin Tablet 20/10 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
(Ltd) Donggu Bio Pharmaceutical
Appearance
White or yellowish round film-coated tablet
Packaging
30 tablets/box [10 tablets/Alu-Alu x 3]
Approval status
Expired

MFDS item code 202003968 · Approved 2020.05.28

This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.
Child dose
Children under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
(Ltd) Donggu Bio Pharmaceutical

Efficacy & effects

Treatment of hypertension and dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • stroke
  • myocardial infarction
View approved original text

This medication is prescribed for patients who need to use the two drugs Olmesartan Medoxomil and Rosuvastatin in combination. Olmesartan Medoxomil is used to treat essential hypertension, helping to lower blood pressure and reduce the risk of cardiovascular disease. Rosuvastatin assists in the treatment of hypercholesterolemia and dyslipidemia, serving as an adjunctive treatment when dietary management alone is insufficient. Additionally, it is effective in reducing the risk of cardiovascular diseases and slowing the progression of atherosclerosis, as well as lowering the risk of stroke and myocardial infarction. Thus, this medication is used to manage hypertension and hyperlipidemia simultaneously to improve cardiovascular health.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each of the active ingredients, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10mg once daily, regardless of meals. If blood pressure is not adequately controlled at this dose, increase to 20mg once daily. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 40mg daily. The blood-pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum at about 8 weeks. If blood pressure is not controlled with this medicine alone, it may be given in combination with a thiazide diuretic, such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day (e.g., in the morning), if possible. For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with close monitoring of their condition. 2. Elderly patients No dose adjustment is needed when this medicine is administered to patients aged 65 years or older. Although no overall differences in efficacy or safety have been observed between elderly and younger patients, a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild or moderate renal impairment (creatinine clearance 30-60mL/min) is 20mg once daily. 4. Patients with hepatic impairment No dose adjustment is needed for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10mg once daily, and it may be increased to a maximum of 20mg daily. Since there is no experience with use in patients with severe hepatic impairment, administration of this medicine is not recommended. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients No dose adjustment is needed. 3. Patients with renal impairment No dose adjustment is needed for patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product with the same strengths of each active ingredient) for convenience.

Child dose

Children under 18 years of age: Safety and efficacy have not been established.

Precautions

This medication may cause severe harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; hence, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication or its components, pregnant women or those who may become pregnant, breastfeeding women, and patients with severely impaired kidney or liver function should not use this medication. It should also not be given to patients undergoing kidney dialysis, patients with severely impaired kidney function, those with severe liver dysfunction, patients with bile duct obstruction, and individuals with certain muscle disorders. Since this medication contains lactose, it should not be taken by patients with lactose intolerance or certain genetic metabolic disorders. Patients with low blood volume or insufficient sodium levels may experience low blood pressure symptoms upon initial use of this medication, so they must be monitored carefully, and appropriate treatment is necessary if low blood pressure occurs. Patients with reduced kidney function should regularly check their serum potassium and creatinine levels, and safety has not been established for patients who have undergone kidney transplantation. As there is a risk of hyperkalemia, patients with heart failure or kidney issues should periodically check their serum potassium levels. This medication can lower blood pressure, so it should be used cautiously in patients with aortic or mitral valve stenosis and obstructive heart disease. Muscle-related side effects such as myalgia, myopathy, and rarely rhabdomyolysis may occur; thus, any unusual symptoms should be reported to a healthcare professional immediately. During the use of this medication, it is advisable to avoid alcohol consumption and undergo regular liver function tests, with even greater caution advised for those with a history of hypothyroidism or other muscular disorders. This medication may interact with other drugs, so it is essential to inform healthcare professionals about any other medications being taken. Pregnant or breastfeeding women should not take this medication, and women planning to become pregnant should use appropriate contraception. The safety and efficacy in children and adolescents under 18 years of age have not been established. In cases of overdose, symptoms such as low blood pressure and palpitations may occur; therefore, immediate consultation with medical staff and appropriate treatment are necessary. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

Increased ALT, Increased AST, Elevated serum creatinine, Decreased creatinine clearance, Headache, Dizziness, Sensory impairment, Neuromyopathy, Drowsiness, Gastroesophageal reflux disease, Constipation, Dental caries, Dyspepsia, Gastric ulcer, Gastritis, Gastroenteritis, Musculoskeletal rigidity, Atrial fibrillation, Hypoglycemia, Chest pain, Tooth extraction, Chest discomfort, Peripheral edema, Vertigo, Abdominal pain, Nausea, Palpitations, Hypercholesterolemia, Dyslipidemia, Hyperuricemia, Arthralgia, Arthritis, Myalgia, Rash, Facial edema, Asthenia, Angioedema, Anaphylactic reaction, Vomiting, Chronic malabsorption syndrome, Rhabdomyolysis, Hyperkalemia, Acute renal failure, Hair loss, Pruritus, Hives, Autoimmune hepatitis, Positional vertigo, Elevated blood pressure, Low back pain, Chest discomfort, Cough, Epistaxis, Upper respiratory tract infection, Asthma, Constipation, Nausea, Abdominal pain, Pancreatitis, Pruritus, Rash, Hives, Myalgia, Myopathy, Rhabdomyolysis, Asthenia, Polyneuropathy, Amnesia, Peripheral neuropathy, Shortness of breath, Diarrhea, Thrombocytopenia, Jaundice, Hepatitis, Stevens-Johnson syndrome, Eosinophilia with systemic symptom drug reaction syndrome, Lupus-like syndrome, Muscle rupture, Arthralgia, Immune-mediated necrotizing myopathy, Hematuria, Edema, Depression, Sleep disorders, Interstitial lung disease, Sexual dysfunction, Gynecomastia, Fatal and non-fatal liver failure, Cognitive impairment, Severe muscle weakness, Ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to maintain the storage temperature between 1 and 30 degrees Celsius. This will help preserve the medication's effectiveness and ensure safe usage.

Appearance and packaging

Appearance

White or yellowish round film-coated tablet

Package unit

30 tablets/box [10 tablets/Alu-Alu x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.